Treace Medical Concepts, Inc. (TMCI)

From the record

Treace Medical Concepts, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Treace Medical Concepts, Inc.'s 7 filed years say what it did: revenue went from $39 million in fiscal 2019 to $213 million in fiscal 2025, up 32.4% a year; it rose in 6 of 6 years; it never fell from a peak; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Treace Medical Concepts, Inc. lost about 68 cents for every dollar of shareholders' money, and gross profitability: its products earned about 89 cents per dollar of everything the company owns. Leverage: it owed about 54 cents per dollar of assets, and net share issuance: its share count grew 1.9% over the year (the filed statements).

From the record

Treace Medical Concepts, Inc.'s standing among 109 graded names in its industry family: revenue of $213 million in fiscal 2025 ranks in the top 38% by size; a net margin of -27.7% ranks in the bottom 46%; revenue growth of 14.5% a year over the last 3 filed years ranks in the top 49% (its annual reports).

From the record

Treace Medical Concepts, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Treace, John T. (Chief Executive Officer, as filed), filing under that title since 2021-04-22, 5.6 years (top 44% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 44%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 20%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Treace Medical Concepts, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $11 million against debt of $56 million leaves -23.5% of its assets as net cash, bottom 14% of its family; cash from operations less capital spending is -13.9% of revenue (bottom 45%); a gross margin of 79.8% (top 13%); research spending of 9.5% of revenue (bottom 42%) (its annual report).

From the record

Treace Medical Concepts, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 14.5% a year over the last three filed years against 32.4% over all 7, slowing (bottom 19% of its family); the newest year grew 1.6% (bottom 25%); research spending grew 14.3% a year (top 30%); capital spending grew -3.1% a year (bottom 48%) (its annual reports). Treace Medical Concepts, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Treace Medical Concepts, Inc.'s newest year against its own record: revenue of $213 million in fiscal 2025 came in 16.4% below the $254 million its prior three years' pace pointed to (bottom 26% of its family); net income of $59 million against a prior three-year average of $49 million (bottom 29%); a net margin of -27.7% against -27.8% before (bottom 28%) (its annual reports).